Quotes 5-day view Delayed Nasdaq
01/11/2021
01/12/2021
01/13/2021
01/14/2021
01/15/2021
Date
179.04(c)
180.37(c)
176.69(c)
175.86(c)
185.75(c)
Last
496 557
801 436
654 090
592 832
1 354 024
Volume
+0.78% +0.74% -2.04% -0.47% +5.62% Change
Sales 2020
2 159 M - -
Net income 2020
595 M - -
Net cash position 2020
1 942 M - -
P/E ratio 2020
56,3x
Yield 2020
-
Sales 2021
1 813 M - -
Net income 2021
-13,9 M - -
Net cash position 2021
2 374 M - -
P/E ratio 2021
-5 067x
Yield 2021
-
Capitalization
33 601 M 33 601 M -
EV / Sales 2020
14,7x
EV / Sales 2021
17,2x
Nbr of Employees
1 605
Free-Float
99,4%
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV...
Notations Surperformance© of Seagen Inc.
Trading Rating : Investor Rating :
All news about SEAGEN INC.
News in other languages on SEAGEN INC.
Analyst Recommendations on SEAGEN INC.
Wall Street closes broadly higher on deal news, vaccine hopes
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SEAGEN INC.
Short Term Mid-Term Long Term Trends Bearish Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
19
Average target price
198,59 $
Last Close Price
185,75 $
Spread / Highest target
36,7%
Spread / Average Target
6,91%
Spread / Lowest Target
-25,7%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
